Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alternative tobacco bill in Senate

This article was originally published in The Tan Sheet

Executive Summary

Sen. Richard Burr, R-N.C., introduces the Federal Tobacco Bill, S. 579, to establish an agency to regulate the manufacture, marketing and use of tobacco products under the Department of Health and Human Services. The legislation is similar to the Youth Prevention and Tobacco Harm Reduction Act, H.R. 1261, introduced March 3 by Rep. Steve Buyer, R-Ind. (1"The Tan Sheet" March 9, 2009, p. 3). During an Energy and Commerce Committee markup March 4, Buyer touted his tobacco bill as an alternative to Chairman Henry Waxman's, D-Calif., Family Smoking Prevention and Tobacco Control Act, H.R. 1256, which would make tobacco an FDA-regulated product. Waxman's bill passed the committee and will move to a floor vote

You may also be interested in...

Tobacco Oversight Looks More Likely, But Is It Bad For FDA’s Health?

The likelihood of Congress handing FDA responsibility for regulating tobacco has ignited debate over whether the new purview would distract an already struggling agency from its mission

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts